In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...